

PRODUCT SHEET

SeraSeq® Myeloid Reference Materials: DNA, RNA Fusion, ctDNA

Comprehensive reference materials for development, validation and clinical application of targeted NGS assays for myeloid diseases

INTRODUCTION

To help clinical labs performing NGS-based myeloid testing understand and characterize their assays, SeraCare has developed a comprehensive set of myeloid cancer NGS reference materials in DNA, fusion RNA and ctDNA formats to maximize compatibility with existing and emerging myeloid assays.

These unique products include a wide range of mutation types, from clinically important SNVs to complex gene fusions. Develop and validate your assay with confidence using the most comprehensive patient-like reference materials on the market for myeloid cancers and ensure robust sensitivity using a single sample with clinically relevant mutations across a range of variant allele frequencies that establish and challenge your assay's limit of detection (LOD).

FEATURES

- 23 DNA variants in SeraSeq Myeloid Mutation DNA Mix (including FLT3 ITDs and NPM1)
- 9 RNA fusions in SeraSeq Myeloid Fusion RNA Mix (including BCR-ABL and PML-RARA)
- 25 DNA variants in SeraSeq Myeloid ctDNA Mix (including FLT3 ITDs, NPM1 and now EZH2 and IDH2)
- Variants precisely quantified using highly sensitive digital PCR assays, and blended with a single well-characterized genomic background (GM24385)
- Validated by targeted NGS panels
- Manufactured in GMP-compliant, ISO 13485-certified facilities

HIGHLIGHTS

Multiplexed format;
Patient-like sample
performance

Quantitated with digital
PCR and validated
with NGS; Assures
accurate and consistent
detection of clinically
relevant mutations

High-quality
manufactured
reference material

ORDERING INFORMATION

Product	Format	Part Code	Allele Freq.	Conc.	Fill Volume	Total Mass
SeraSeq Myeloid Mutation DNA Mix	Purified DNA in buffer	0710-0408	5%–15%	15 ng/μL	25 μL	375 ng
SeraSeq Myeloid Fusion RNA Mix	Purified RNA in buffer	0710-0407	N/A	15 ng/μL	25 μL	375 ng
SeraSeq Myeloid ctDNA Mix	Purified ctDNA in buffer	0710-2646	WT	15 ng/μL each	25 μL each	375 ng each
		0710-2647	0.1%			
		0710-2648	0.5%			
		0710-2649	1%			

Beratung und
Vertrieb in
Deutschland &
Österreich:



HiSS Diagnostics GmbH
Tullastr. 70
79108 Freiburg
Germany

Telefon: +49 761 389 49 0
Fax: +49 761 389 49 20
Email: hiss@hiss-dx.de
Web: www.hiss-dx.de

SERASEQ MYELOID MUTATION DNA MIX & SERASEQ MYELOID CTDNA MIX

Gene ID	HGVS	DNA	ctDNA
ABL1	c.944C>T	●	●
ASXL1	c.1900_1922del	●	●
ASXL1	c.1934dup	●	●
BRAF	c.1799T>A	●	●
CALR	c.1099_1150del	●	●
CBL	c.1139T>C	●	●
CBL	c.1259G>A	●	●
CEBPA	c.68dup	●	●
CEBPA	c.937_939dup	●	●
CSF3R	c.1853C>T	●	●
EZH2	c.1937A>T	✗	●
FLT3	c.1759_1800dup	●	●
FLT3	c.1806_1807insGGGGCTTTCAG-AGAATATGAATATGATCTCAAA	●	●

Gene ID	HGVS	DNA	ctDNA
FLT3	c.2503G>T	●	●
IDH1	c.394C>T	●	●
IDH2	c.419G>A	✗	●
IDH2	c.515G>A	✗	●
JAK2	c.1624_1629del	●	●
JAK2	c.1849G>T	●	●
MPL	c.1544G>T	●	●
MYD88	c.755T>C	●	●
NPM1	c.860_863dup	●	●
SF3B1	c.1998G>T	●	●
SF3B1	c.2098A>G	●	●
SRSF2	c.284_307del	●	●
U2AF1	c.101C>T	●	✗

● included ✗ not included

SERASEQ MYELOID FUSION RNA MIX

Gene ID	HGVS
BCR-ABL1	BCR{NM_004327.3}:r.1_3378_ABL{NM_005157.3}:r.83_5384
ETV6-ABL1 (transcript 1)	ETV6{NM_001987.4}:r.1_737_ABL1{NM_007313.2}:r.576-5881
ETV6-ABL1 (transcript 2)	ETV6{NM_001987.4}:r.1_1283_ABL1{NM_007313.2}:r.576-5881
FIP1L1-PDGFRFA	FIP1L1{NM_030917.3}:r.1_1109_PDGFRFA{NM_006206.5}:r.2037_6590
MYST3-CREBBP	MYST3{NM_006766.4}:r.1_3803_CREBBP{NM_004380.2}:r.290_10197
PCM1-JAK2	PCM1{NM_006197.3}:r.1_4365_JAK2{NM_004972.3}:r.2008_5285
PML-RARα	PML{NM_033238.2}:r.1_1786_ins134bp_RARA{NM_000964.3}:r.657_3301
RUNX1-RUNX1T1	RUNX1 {NM_001754.4}: r.1-803_RUNX1T1 {NM_004349.3}:r.419-7420
TCF3-PBX1	TCF3{NM_003200.3}:r.1_1519_PBX1{NM_002585.3}:r.729_6918

ABOUT US

SeraCare offers a comprehensive portfolio of reference materials for oncology and reproductive health, designed and manufactured to meet the precision demanded by NGS assays. The portfolio includes high quality ground-truth RNA, ctDNA and genomic DNA-based reference materials that are NGS platform agnostic for tumor profiling, immuno-oncology, liquid biopsy, NIPT and germline cancer assay workflows. **For more information visit seracare.com**

FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES. Seraseq® is a registered trademark of LGC Clinical Diagnostics, Inc. © 2022 LGC Clinical Diagnostics, Inc. All rights reserved.